Your session is about to expire
← Back to Search
AZD4205 for PTCL
Study Summary
This trial is to see if a new drug is safe and effective in treating patients with a specific type of cancer who have not responded to other treatments.
- Relapsed or Refractory Peripheral T Cell Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You cannot have had too many treatments for lymphoma before, except for bone marrow transplant or radiation therapy.You have a medical condition called "peripheral T-cell lymphoma" that has been diagnosed by a doctor.What treatments have you received before? Check all that apply.You have peripheral T-cell lymphoma that may not respond well to anti-lymphoma treatment or may come back after treatment.This is not an exclusion criterion, it is a prompt for the participant to select any relevant medical conditions they may have.Are you willing to take part in a research study, follow its rules, and go to the hospital for check-ups as needed?
- Group 1: AZD4205 Group A
- Group 2: AZD4205 Group B
- Group 3: AZD4205 Group C
- Group 4: AZD4205 Group D
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical centers in the US are actively conducting this research project?
"This trial has 5 operational centers, such as Winship Cancer Institute of Emory University in Atlanta, The University of Texas MD Anderson Cancer Center in Houston and Yale Cancer Centre in New Haven. Additionally there are two other sites where the study is taking place."
What is the current maximum capacity for participants in this research endeavor?
"A total of 160 participants meeting pre-determined eligibility requirements are required for this study. The Winship Cancer Institute of Emory University in Atlanta and the MD Anderson Centre at UT Houston have been identified as trial sites."
Are there still vacancies for this research endeavor?
"Confirmed. Clinicaltrials.gov states that this medical study is actively recruiting patients, with the initial post dating back to September 10th 2019 and last update occurring on August 25th 2022."
To what degree is AZD4205 hazardous to people's health?
"There is an adequate amount of evidence to suggest that AZD4205 is safe, thus it was given a score of 2. This being said, no clinical data exists in support of the drug's effectiveness."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Most responsive sites:
- The University of Texas MD Anderson Cancer Center: < 48 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger